EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal

Evommune’s shares dropped after its Phase IIb CSU study missed the primary endpoint, leading the company to halt further development of EVO756 for the indication. The negative clinical result is a major hit to the program’s near-term prospects and likely pressures investor expectations for subsequent milestones.

Analysis

Evommune’s shares dropped after its Phase IIb CSU study missed the primary endpoint, leading the company to halt further development of EVO756 for the indication. The negative clinical result is a major hit to the program’s near-term prospects and likely pressures investor expectations for subsequent milestones.